Neurocrine Biosciences INC Form 4 insider transactions

Julie Cooke, Chief Human Resources Officer at Neurocrine Biosciences, exercised stock options for 6,468 shares of common stock at a price of $61.82 on May 16, 2025.

Director William Rastetter exercised stock options and sold 30,000 shares of Neurocrine Biosciences under a pre-arranged 10b5-1 trading plan.

Chief Human Resources Officer Julie Cooke reports the acquisition and disposal of Neurocrine Biosciences stock and derivative securities, including transactions under 10b5-1 trading plans.

Director Kevin Gorman reports the vesting of Restricted Stock Units (RSUs) and subsequent sale of Neurocrine Biosciences (NBIX) common stock under pre-arranged 10b5-1 trading plans.

Director Stephen Sherwin sold 13,831 shares of Neurocrine Biosciences (NBIX) common stock at an average price of $116.6888 under a pre-arranged 10b5-1 trading plan.

Eiry Roberts, Chief Medical Officer of Neurocrine Biosciences, reports the acquisition and disposition of common stock and derivative securities, including stock options and restricted stock units, through both market sales and vesting events.

Chief Scientific Officer of Neurocrine Biosciences, Jude Onyia, reports acquisition and disposal of common stock and derivative securities, including stock options and restricted stock units, through both market sales and vesting.

Darin Lippoldt, Chief Legal Officer of Neurocrine Biosciences, reports the acquisition and disposal of common stock and derivative securities, including stock options and restricted stock units, through both market sales and vesting events.

CEO Kyle Gano exercised stock options and sold shares of Neurocrine Biosciences (NBIX) common stock under pre-arranged 10b5-1 trading plans.

Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, reports the acquisition and disposal of common stock and restricted stock units.

David W. Boyer, Chief Corporate Affairs Officer of Neurocrine Biosciences, reports the acquisition and disposition of common stock and derivative securities, including stock options and restricted stock units, through both market sales and vesting.

Chief Commercial Officer Eric Benevich of Neurocrine Biosciences reports acquisition and disposal of common stock and derivative securities, including stock options and restricted stock units, under a pre-arranged trading plan.

Chief Financial Officer of Neurocrine Biosciences, Matt Abernethy, reports acquisition and disposition of common stock and derivative securities, including stock options and restricted stock units, through both market sales and vesting.

Chief Human Resources Officer Julie Cooke of Neurocrine Biosciences reports the vesting of restricted stock units and subsequent sale of shares under a pre-arranged trading plan.

Director Kevin Gorman reports the vesting of restricted stock units and the sale of Neurocrine Biosciences (NBIX) stock under a pre-arranged 10b5-1 trading plan.

Eiry Roberts, Chief Medical Officer of Neurocrine Biosciences, reports the vesting of restricted stock units and subsequent sale of shares under a pre-arranged 10b5-1 trading plan.

Darin Lippoldt, Chief Legal Officer of Neurocrine Biosciences, reported the vesting of restricted stock units and the sale of common stock under a pre-arranged Rule 10b5-1 trading plan.

Neurocrine Biosciences CEO Kyle Gano exercised stock options and sold a portion of the acquired shares under a pre-arranged 10b5-1 trading plan.

David Boyer, Chief Corporate Affairs Officer of Neurocrine Biosciences, reports the vesting of restricted stock units and subsequent sale of shares under a pre-arranged 10b5-1 trading plan.

Chief Commercial Officer Eric Benevich of Neurocrine Biosciences reports the vesting of restricted stock units and subsequent sale of shares under a pre-arranged 10b5-1 trading plan.

Chief Financial Officer of Neurocrine Biosciences, Matt Abernethy, reports the acquisition and disposition of common stock and restricted stock units.

Julie Cooke, Chief Human Resources Officer of Neurocrine Biosciences, reported the vesting of restricted stock units and subsequent sale of shares under pre-arranged trading plans.

Director Kevin Gorman exercised stock options and sold shares of Neurocrine Biosciences (NBIX) under a pre-arranged 10b5-1 trading plan.

Eiry Roberts, Chief Medical Officer of Neurocrine Biosciences, reports the vesting of restricted stock units and subsequent sale of shares under a pre-arranged trading plan.

Jude Onyia, Chief Scientific Officer of Neurocrine Biosciences, reports the vesting of restricted stock units and subsequent sale of shares under a pre-arranged 10b5-1 trading plan.

Darin Lippoldt, Chief Legal Officer of Neurocrine Biosciences, reports the vesting of restricted stock units and subsequent sale of shares under a pre-arranged 10b5-1 trading plan.

Neurocrine Biosciences CEO Kyle Gano exercised stock options and sold shares of common stock on January 31, 2025, under a pre-arranged 10b5-1 trading plan.

Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, reports the acquisition and disposal of common stock and restricted stock units (RSUs) on January 31, 2025, and February 3, 2025, under a pre-arranged trading plan.

David W. Boyer, Chief Corporate Affairs Officer of Neurocrine Biosciences, reports the vesting of restricted stock units and subsequent sale of shares under a pre-arranged trading plan.

Chief Commercial Officer Eric Benevich of Neurocrine Biosciences reports the sale of 1,207 shares of common stock under a pre-arranged 10b5-1 trading plan.